Basic information about the drug Levaquin

Pharmacological action

antibacterial broad-spectrum bactericidal.

Levaquin is one of the most popular antibiotics. It is used for a variety of infections.

Release Form

Tablets, film-coated: biconvex, round, yellow, in cross section shows two layers (5, 7 or 10 pieces in blisters, for 1-5 or 10 packs per carton box, 3 pieces in contour cell.. packages, 1 package in carton box; 5, 10, 20, 30, 40, 50 or 100 pieces in cans or bottles, 1 jar or bottle in a cardboard bundle).;

Infusion solution: clear, yellowish-green (100 ml in the bottles or vials, 1 vial or bottle in a cardboard bundle);

Drops eye 0.5%: transparent, yellowish-green in color (1 ml in tubes, droppers, for 2 tubes in a carton box; 5 or 10 ml vials with dropper cap, 1 bottle in a cardboard bundle).

The composition 1 tablet contains: Levofloxacin — 250 or 500 mg (levofloxacin hemihydrate — 256.23 and 512.46 mg); Auxiliary components (tablets of 250 or 500 mg respectively): Microcrystalline cellulose — 30.83 / 61.66 mg Hypromellose — 8.99 / 17.98 mg Croscarmellose sodium — 9.3 / 18.6 mg Polysorbate 80 — 1.55 / 3.1 mg calcium stearate — 3.1 / 6.2 mg.

levaquin

levaquin

A16.9 Respiratory tuberculosis unspecified, without mention of bacteriological or histological confirmation

A41.9 Septicaemia, unspecified

H10 Conjunctivitis

J01 Acute sinusitis

J12.2 Pneumonia

J15.2 Pneumonia caused by Staphylococcus

J15.4 Pneumonia due to other streptococci

J15.7 Pneumonia caused by Mycoplasma

J16.0 Pneumonia due to chlamydia

J16.8 Pneumonia due to other specified infectious agents

J20 Acute bronchitis

J20.1 Acute bronchitis due to Haemophilus influenzae [wand-Afanasyeva Pfeiffer]

J20.2 Acute bronchitis due to streptococcus

J20.4 Acute bronchitis is caused by parainfluenza virus

J20.8 Acute bronchitis due to other specified agents

K65 Peritonitis

L01 Impetigo

L02 skin abscesses, boils and carbuncles

L03.9 Cellulitis, unspecified

L08.0 Pyoderma

L08.9 Local infection of skin and subcutaneous tissue, unspecified

N10 Acute tubulointerstitial nephritis

N39.0 Urinary tract infection without the current locale

N41.1 Chronic prostatitis

R78.8.0 * Bacteremia

T79.3 Post-traumatic wound infection, not elsewhere classified

Contraindications:

Hypersensitivity (including to other quinolones).

Restrictions apply

1. Age 18 years (Safety and efficacy have not been determined);

2. –źrthropathy and osteochondrosis in young growing animals of various species.

3. Precautions: diagnosed or suspected CNS disorders, accompanied by a predisposition to seizures or decrease seizure threshold (epilepsy, severe cerebral arteriosclerosis); the presence of other risk factors for seizures or reduce seizure threshold (concomitant use of certain drugs, impaired renal function); Simultaneous treatment with corticosteroids (increased risk of tendinitis), lack of glucose-6-phosphate dehydrogenase (possible hemolysis).

4. In ophthalmology: up to 1 year (safety and efficacy have not been determined).

Side effects

Nausea (1.3%), diarrhea (1%), vaginitis (0.7%), insomnia (0.5%), abdominal pain (0.4%), flatulence (0.4%), pruritus (0 , 4%), dizziness (0.3%), dyspepsia (0.3%), rash (0.3%), genital candidiasis (0.2%), taste disturbance (0.2%), vomiting (0 , 2%), constipation (0.1%), a fungal infection (0.1%), pruritus in the genital area (0.1%), headache (0.1%), yeast (0.1%) nervousness (0.1%), erythematous rash (0.1%), rash (0.1%). In case of side effects, contact your doctor.

From the nervous system and sensory organs: headache (6.4%), insomnia (4.6%), dizziness (2.7%), fatigue (1.2%) violation of taste sensitivity (1%); <1%: fatigue, impaired coordination, coma, seizures, speech disorder, stupor, tremor, vertigo, confusion, aggression, agitation, anxiety, anorexia, delirium, depression, emotional lability, hallucinations, impaired concentration, mania, nervousness, paranoia, abnormal thinking, abnormal dreams, sleep disorder, somnolence, diplopia, cerebrovascular disorders, tinnitus, hearing loss and vision, conjunctivitis. The antibiotic should be changed.

Cardio-vascular system and blood <1%: hypertension, hypotension (including orthostatic), heart failure, circulatory failure, arrhythmia, tachycardia, blockades, cardiac arrest, supraventricular tachycardia, atrial fibrillation or flutter, palpitations , angina, coronary thrombosis, myocardial infarction, thrombosis, phlebitis, pathology platelets, epistaxis, purpura, thrombocytopenia, leukocytosis, leukopenia, lymphadenopathy. It is necessary to change the dosage.

The respiratory system: sinusitis (1.3%), rhinitis (1%); <1%: asthma, acute respiratory distress syndrome, cough, hemoptysis, dyspnea, hypoxia, pleural effusion, respiratory distress.

From the digestive tract: nausea (7.2%), diarrhea (5.6%), constipation (3.2%), abdominal pain (2.5%), dyspepsia (2.4%), vomiting (2 , 3%), flatulence (1.5%); <1%: dry mouth, dysphagia, swelling of the tongue, gastroenteritis, gastrointestinal hemorrhage, pseudomembranous colitis, hepatic coma, increased LDH, jaundice, abnormal liver function.

From the nervous system and sensory organs: headache (6%), dizziness (3%), insomnia (4%); 0.1-1%: anxiety, agitation, confusion, depression, hallucinations, nightmares, insomnia, anorexia, abnormal dreams, tremor, convulsions, vertigo, hypertension, hyperkinesia, incoordination, drowsiness, fainting.

Cardio-vascular system and blood: 0.1-1%: anemia, arrhythmia, palpitations, cardiac arrest, supraventricular tachycardia, phlebitis, epistaxis, thrombocytopenia.

From the respiratory system: dyspnea (1%).

From the digestive tract: nausea (7%), diarrhea (5%), constipation (3%), abdominal pain (2%), dyspepsia (2%), vomiting (2%); 0.1-1%: gastritis, stomatitis, pancreatitis, esophagitis, gastroenteritis, glossitis, pseudomembranous colitis, abnormal liver function, increased liver enzymes, increased alkaline phosphatase.

From the urogenital system: vaginitis (1%); 0.1-1%: renal dysfunction, acute renal failure, genital candidiasis.

From the musculoskeletal system: 0.1-1%: arthralgia, tendonitis, myalgia, pain in the skeletal muscle.

For the skin: rash (2%), pruritus (1%); 0.1-1%: allergic reactions, edema (1%), urticaria.

Other: candidiasis (1%), the reaction at the site of the on / in (1%), chest pain (1%); 0.1-1%: Hypoglycemia / hyperglycemia, hyperkalemia.

From the urogenital system: vaginitis (1.8%); <1%: itching in the genital area, abnormal ejaculation, impotence, increased level of creatinine in serum, decreased renal function, acute renal failure, hematuria.

On the part of the musculoskeletal system <1%: arthralgia, arthritis, arthrosis, muscular weakness, myalgia, osteomyelitis, synovitis, tendonitis, rhabdomyolysis, hyperkinesia, involuntary muscle contractions, increased muscle tone, paralysis.

For the skin: itching (1.3%), rash (1.2%); <1%: erythema nodosum, skin peeling, skin ulceration, rash, increased sweating.

Other: local reaction (3.5%), pain (1.7%) and inflammation (1.1%) at the injection site; pain (1.4%), chest pain (1.2%) and a back (1,1%); <1%: hyperkalemia, hypokalemia, dehydration, hypoglycemia, hyperglycemia, exacerbation of diabetes mellitus, weight loss, cancer, fever, swelling of the face, withdrawal syndrome.

In post-marketing studies have reported the following side effects: allergic pneumonitis, anaphylactic shock, anaphylactoid reactions, dysphonia, abnormal EEG, encephalopathy, eosinophilia, erythema multiforme, hemolytic anemia, multiple organ failure, the increase in the international normalized ratio (INR), torsades de pointes ventricular vasodilation.

Overdose

ataxia, ptosis, decreased locomotors activity, dyspnea, prostration, tremors, convulsions.

Treatment of acute overdose: gastric lavage, adequate hydration. Not reported by hemodialysis and peritoneal dialysis.

Antibiotics can be used for both adults and children.